查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611045

美國用於自體免疫疾病的 IVD 和 LDT 市場規模、佔有率和趨勢分析報告：按類型、技術、應用和細分市場預測，2025-2030 年

U.S. IVD And LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Type, By Technology (Immunoassays, Clinical Chemistry, Molecular Diagnostics), By Application (Psoriasis, Crohn's Disease), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

美國自體免疫疾病 IVD 和 LDT 市場的成長和趨勢

根據Grand View Research, Inc.的最新報告，預計到2030年，美國自體免疫疾病IVD和LDT市場規模將達到38.8億美元，2025年至2030年複合年成長率為6.6%。自體免疫疾病的高盛行率、人們對這些疾病的認知不斷提高、對技術開發和高性能產品的需求不斷成長以及研發的高投資是推動市場成長的因素。

這些健康問題是美國慢性病的第二大原因，也是美國女性死亡的主要原因之一。這些疾病對患者的勞動生產力和生活品質產生負面影響，並造成經濟負擔，對美國的醫療費用支出重大影響。美國國立衛生研究院實驗室估計，與這些疾病相關的直接醫療費用約為 1,000 億美元，其中癌症醫療費用高達 570 億美元。

受這些疾病影響的人數眾多，其盛行率以驚人的速度上升，導致美國醫療保健成本增加，這些都是優先事項，因此預計將推動成長。此外，此類健康疾病導致的併發症，如內臟器官損傷、運動能力下降和死亡風險，使得此類疾病的早期診斷和介入極為重要。人們對這種情況的認知不斷提高預計將推動市場成長。

許多研究人員認為，全球自體免疫疾病的增加是由於遺傳傾向和環境因素造成的。然而，人們對於環境中什麼因素引發自體免疫疾病的了解卻甚少。

儘管FDA將體外診斷作為醫療設備進行監管，但過去並無權監管LDT。隨後，FDA宣布將利用醫療設備監管權限對LDT進行監管。一些研究人員認為，FDA對LDT的監管將增加測試開發所需的時間和成本。

美國自體免疫疾病 IVD 和 LDT 市場報告亮點

  • IVD 領域預計將在 2024 年獲得顯著的市場佔有率，並在預測期內以 6.26% 的複合年成長率成長。
  • 2024 年，乾癬比例最高為 15.21%，預計在整個預測期內將保持其主導地位。乾癬患病率的上升以及 NPF 為提高診斷準確性而採取的策略性舉措是促進該領域成長的關鍵因素。
  • 臨床化學板塊2024年收益佔有率最大，為30.32%。臨床化學測試在患者各種疾病的檢測和診斷中發揮核心作用。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • SWOT 分析（依因素）
  • 產業分析-波特五力分析
  • 消費行為分析
  • 目標疾病族群
  • 監管場景
  • 贖回場景
  • 分析未滿足的需求和機會

第 4 章 類型業務分析

  • 美國自體免疫疾病IVD和LDT市場：類型變異分析
  • 體外診斷
    • IVD市場，2018-2030
    • 依技術
    • 按用途
  • LDDT
    • LDT市場，2018-2030
    • 依技術
    • 按用途

第5章技術業務分析

  • 美國自體免疫疾病IVD和LDT市場：技術波動分析
  • 免疫測定法
    • 免疫分析市場，2018-2030
  • 臨床化學
    • 臨床化學市場，2018-2030
  • 血液學
    • 血液學市場，2018-2030
  • 凝固
    • 凝固市場，2018-2030
  • 微生物學
    • 微生物學市場，2018-2030
  • 分子診斷
    • 分子診斷市場，2018-2030
  • 其他
    • 其他市場，2018-2030

第6章 應用業務分析

  • 美國自體免疫疾病IVD和LDT市場：應用變化分析
  • 愛迪生氏症
    • 愛迪生氏症市場，2018-2030
  • 僵直性脊椎炎
    • 僵直性脊椎炎市場，2018-2030
  • 脫髮症
    • 脫髮症市場，2018-2030
  • 類風濕性關節炎
    • 類風濕性關節炎市場，2018-2030
  • 全身性紅斑性狼瘡
    • 全身性紅斑性狼瘡市場，2018-2030
  • 系統性硬皮症
    • 全身性硬化症市場，2018-2030
  • 乾癬
    • 乾癬市場，2018-2030
  • 抗磷脂抗體症候群
    • 抗磷脂抗體症候群市場，2018-2030
  • 1型糖尿病
    • 1 型糖尿病市場，2018-2030
  • 克隆氏症
    • 克隆氏症市場，2018-2030
  • 潰瘍性大腸炎
    • 潰瘍性大腸炎市場，2018-2030
  • 發作性睡病
    • 發作性睡病市場，2018-2030
  • 多發性硬化症
    • 多發性硬化症市場，2018-2030
  • 葡萄膜炎
    • 葡萄膜炎市場，2018-2030
  • 其他
    • 其他市場，2018-2030

第7章 競爭格局

  • 公司分類
  • 策略規劃
    • 新產品發布
    • 夥伴關係與協作
    • 併購
    • 其他
  • 2024 年企業市場佔有率分析
  • 公司簡介/上市公司
    • Adaptive BIoTechnologies Corporation
    • Agilent Technologies, Inc
    • Bio-Rad Laboratories, Inc.
    • bioMerieux, Inc.
    • Corgenix, Inc.（Sebia）
    • F. Hoffmann-La Roche Ltd.
    • Quest Diagnostics, Inc.
    • PerkinElmer, Inc
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
Product Code: GVR-1-68038-287-7

U.S. IVD And LDT For Autoimmune Diseases Market Growth & Trends:

The U.S. IVD and LDT for autoimmune diseases market size is expected to reach USD 3.88 billion by 2030, growing at a CAGR of 6.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The high prevalence of autoimmune disorders, growing awareness about these ailments, growing demand for technologically developed & high performance products, and high investments in research are the driving factors for the expanding growth of the market.

These health problems are second leading cause of chronic illness in the U.S. and are amongst the leading causes of deaths in the U.S. women. They have an adverse impact on the work productivity and the quality of life of patients and form an economic burden greatly affecting the healthcare spending in the U.S. The National Institute of Health estimates the direct healthcare costs associated with these disorders accounted for around USD 100 billion, whereas the cancer costs accounted for USD 57 billion.

A large number of people suffering from these disorders and rising prevalence at an alarming rate resulting in an increase of healthcare spending in the U.S. are all priority concerns, and is thus are expected to drive growth. Furthermore, the complications resulting from such health hazards like damage to internal organs, loss of mobility, and risk of death make it crucial for early diagnosis and intervention of such conditions. The rising awareness about these conditions is expected to lead market growth.

It is believed by number of researchers that the increase in the number of autoimmune diseases globally is due to the genetic predisposition and environmental factors. But there is very little knowledge about what exactly in the environment triggers the occurrence of autoimmune diseases. and mainly focused on commercial kits that are widely used by laboratories.

The FDA regulates IVD as medical devices however in the past it did not use its authority to regulate LDT. The FDA later announced that it would enforce its medical device regulatory authority to regulate the LDTs. Some researchers believe that the FDA regulation on LDTs would lead to an increase in the time and cost required to develop the tests.

U.S. IVD And LDT For Autoimmune Diseases Market Report Highlights:

  • The IVD segment gained a major market share in 2024 and is expected to grow at a CAGR of 6.26% over the forecast period, attributed to its efficient testing for both systemic & organ-specific autoimmune pathologies and better reimbursement policies.
  • Psoriasis held the largest share of 15.21% in 2024 and is expected to maintain a dominant share throughout the forecast period. The rise in psoriasis prevalence and the strategic initiatives undertaken by the NPF to improve diagnostic accuracy are key factors contributing to the segment's growth.
  • The clinical chemistry segment held the largest revenue share of 30.32% in 2024. Clinical chemistry tests play a central role in testing and diagnosing various diseases in patients.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Type Segment
    • 1.2.2. Technology Segment
    • 1.2.3. Application Segment
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Formulation & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objective
    • 1.9.1. Objective 1
    • 1.9.2. Objective2

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Technology Segment Snapshot
  • 2.3. Application Segment Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Emerging chronic diseases patients
      • 3.2.1.2. Increasing number of new FDA injectable generics drugs approvals
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of injectable
  • 3.3. SWOT Analysis, by Factor
  • 3.4. Industry Analysis- Porter's
  • 3.5. Consumer Behavior Analysis
  • 3.6. Target Disease Population
  • 3.7. Regulatory Scenario
  • 3.8. Reimbursement Scenario
  • 3.9. Unmet Needs and Opportunity Analysis

Chapter 4. Type Business Analysis

  • 4.1. U.S. IVD & LDT For Autoimmune Diseases Market: Type Movement Analysis
  • 4.2. IVD
    • 4.2.1. IVD Market, 2018 - 2030 (USD Million)
    • 4.2.2. By Technology
      • 4.2.2.1. Immunoassays
        • 4.2.2.1.1. Immunoassays Market, 2018 - 2030 (USD Million)
      • 4.2.2.2. Clinical Chemistry
        • 4.2.2.2.1. Clinical Chemistry Market, 2018 - 2030 (USD Million)
      • 4.2.2.3. Hematology
        • 4.2.2.3.1. Hematology Market, 2018 - 2030 (USD Million)
      • 4.2.2.4. Coagulation
        • 4.2.2.4.1. Coagulation Market, 2018 - 2030 (USD Million)
      • 4.2.2.5. Microbiology
        • 4.2.2.5.1. Microbiology Market, 2018 - 2030 (USD Million)
      • 4.2.2.6. Molecular Diagnostics
        • 4.2.2.6.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
      • 4.2.2.7. Others
        • 4.2.2.7.1. Others Market, 2018 - 2030 (USD Million)
    • 4.2.3. By Application
      • 4.2.3.1. Addison's Disease
        • 4.2.3.1.1. Addison's Disease Market, 2018 - 2030 (USD Million)
      • 4.2.3.2. Ankylosing Spondylitis
        • 4.2.3.2.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
      • 4.2.3.3. Alopecia Areata
        • 4.2.3.3.1. Alopecia Areata Market, 2018 - 2030 (USD Million)
      • 4.2.3.4. Rheumatoid Arthritis
        • 4.2.3.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
      • 4.2.3.5. Systemic Lupus Erythematosus
        • 4.2.3.5.1. Systemic Lupus Erythematosus Market, 2018 - 2030 (USD Million)
      • 4.2.3.6. Systemic Sclerosis
        • 4.2.3.6.1. Systemic Sclerosis Market, 2018 - 2030 (USD Million)
      • 4.2.3.7. Psoriasis
        • 4.2.3.7.1. Psoriasis Market, 2018 - 2030 (USD Million)
      • 4.2.3.8. Antiphospholipid Antibody Syndrome
        • 4.2.3.8.1. Antiphospholipid Antibody Syndrome Market, 2018 - 2030 (USD Million)
      • 4.2.3.9. Diabetes Type 1
        • 4.2.3.9.1. Diabetes Type 1 Market, 2018 - 2030 (USD Million)
      • 4.2.3.10. Crohn's Disease
        • 4.2.3.10.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
      • 4.2.3.11. Ulcerative Colitis
        • 4.2.3.11.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
      • 4.2.3.12. Narcolepsy
        • 4.2.3.12.1. Narcolepsy Market, 2018 - 2030 (USD Million)
      • 4.2.3.13. Multiple Sclerosis
        • 4.2.3.13.1. Multiple Sclerosis Market, 2018 - 2030 (USD Million)
      • 4.2.3.14. Uveitis
        • 4.2.3.14.1. Uveitis Market, 2018 - 2030 (USD Million)
      • 4.2.3.15. Others
        • 4.2.3.15.1. Others Market, 2018 - 2030 (USD Million)
  • 4.3. LDT
    • 4.3.1. LDT Market, 2018 - 2030 (USD Million)
    • 4.3.2. By Technology
      • 4.3.2.1. Immunoassays
        • 4.3.2.1.1. Immunoassays Market, 2018 - 2030 (USD Million)
      • 4.3.2.2. Clinical Chemistry
        • 4.3.2.2.1. Clinical Chemistry Market, 2018 - 2030 (USD Million)
      • 4.3.2.3. Hematology
        • 4.3.2.3.1. Hematology Market, 2018 - 2030 (USD Million)
      • 4.3.2.4. Coagulation
        • 4.3.2.4.1. Coagulation Market, 2018 - 2030 (USD Million)
      • 4.3.2.5. Microbiology
        • 4.3.2.5.1. Microbiology Market, 2018 - 2030 (USD Million)
      • 4.3.2.6. Molecular Diagnostics
        • 4.3.2.6.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
      • 4.3.2.7. Others
        • 4.3.2.7.1. Others Market, 2018 - 2030 (USD Million)
    • 4.3.3. By Application
      • 4.3.3.1. Addison's Disease
        • 4.3.3.1.1. Addison's Disease Market, 2018 - 2030 (USD Million)
      • 4.3.3.2. Ankylosing Spondylitis
        • 4.3.3.2.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
      • 4.3.3.3. Alopecia Areata
        • 4.3.3.3.1. Alopecia Areata Market, 2018 - 2030 (USD Million)
      • 4.3.3.4. Rheumatoid Arthritis
        • 4.3.3.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
      • 4.3.3.5. Systemic Lupus Erythematosus
        • 4.3.3.5.1. Systemic Lupus Erythematosus Market, 2018 - 2030 (USD Million)
      • 4.3.3.6. Systemic Sclerosis
        • 4.3.3.6.1. Systemic Sclerosis Market, 2018 - 2030 (USD Million)
      • 4.3.3.7. Psoriasis
        • 4.3.3.7.1. Psoriasis Market, 2018 - 2030 (USD Million)
      • 4.3.3.8. Antiphospholipid Antibody Syndrome
        • 4.3.3.8.1. Antiphospholipid Antibody Syndrome Market, 2018 - 2030 (USD Million)
      • 4.3.3.9. Diabetes Type 1
        • 4.3.3.9.1. Diabetes Type 1 Market, 2018 - 2030 (USD Million)
      • 4.3.3.10. Crohn's Disease
        • 4.3.3.10.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
      • 4.3.3.11. Ulcerative Colitis
        • 4.3.3.11.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
      • 4.3.3.12. Narcolepsy
        • 4.3.3.12.1. Narcolepsy Market, 2018 - 2030 (USD Million)
      • 4.3.3.13. Multiple Sclerosis
        • 4.3.3.13.1. Multiple Sclerosis Market, 2018 - 2030 (USD Million)
      • 4.3.3.14. Uveitis
        • 4.3.3.14.1. Uveitis Market, 2018 - 2030 (USD Million)
      • 4.3.3.15. Others
        • 4.3.3.15.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

  • 5.1. U.S. IVD & LDT For Autoimmune Diseases Market: Technology Movement Analysis
  • 5.2. Immunoassays
    • 5.2.1. Immunoassays Market, 2018 - 2030 (USD Million)
  • 5.3. Clinical Chemistry
    • 5.3.1. Clinical Chemistry Market, 2018 - 2030 (USD Million)
  • 5.4. Hematology
    • 5.4.1. Hematology Market, 2018 - 2030 (USD Million)
  • 5.5. Coagulation
    • 5.5.1. Coagulation Market, 2018 - 2030 (USD Million)
  • 5.6. Microbiology
    • 5.6.1. Microbiology Market, 2018 - 2030 (USD Million)
  • 5.7. Molecular Diagnostics
    • 5.7.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

  • 6.1. U.S. IVD & LDT For Autoimmune Diseases Market: Application Movement Analysis
  • 6.2. Addison's Disease
    • 6.2.1. Addison's Disease Market, 2018 - 2030 (USD Million)
  • 6.3. Ankylosing Spondylitis
    • 6.3.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
  • 6.4. Alopecia Areata
    • 6.4.1. Alopecia Areata Market, 2018 - 2030 (USD Million)
  • 6.5. Rheumatoid Arthritis
    • 6.5.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
  • 6.6. Systemic Lupus Erythematosus
    • 6.6.1. Systemic Lupus Erythematosus Market, 2018 - 2030 (USD Million)
  • 6.7. Systemic Sclerosis
    • 6.7.1. Systemic Sclerosis Market, 2018 - 2030 (USD Million)
  • 6.8. Psoriasis
    • 6.8.1. Psoriasis Market, 2018 - 2030 (USD Million)
  • 6.9. Antiphospholipid Antibody Syndrome
    • 6.9.1. Antiphospholipid Antibody Syndrome Market, 2018 - 2030 (USD Million)
  • 6.10. Diabetes Type 1
    • 6.10.1. Diabetes Type 1 Market, 2018 - 2030 (USD Million)
  • 6.11. Crohn's Disease
    • 6.11.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
  • 6.12. Ulcerative Colitis
    • 6.12.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
  • 6.13. Narcolepsy
    • 6.13.1. Narcolepsy Market, 2018 - 2030 (USD Million)
  • 6.14. Multiple Sclerosis
    • 6.14.1. Multiple Sclerosis Market, 2018 - 2030 (USD Million)
  • 6.15. Uveitis
    • 6.15.1. Uveitis Market, 2018 - 2030 (USD Million)
  • 6.16. Others
    • 6.16.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
    • 7.2.1. New Product Launch
    • 7.2.2. Partnership & Collaboration
    • 7.2.3. Merger and Acquisition
    • 7.2.4. Others
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company Profiles/Listing
    • 7.4.1. Adaptive Biotechnologies Corporation
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Agilent Technologies, Inc
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Bio-Rad Laboratories, Inc.
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. bioMerieux, Inc.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Corgenix, Inc. (Sebia)
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. F. Hoffmann-La Roche Ltd.
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Quest Diagnostics, Inc.
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. PerkinElmer, Inc
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Abbott Laboratories
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Thermo Fisher Scientific, Inc.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. IVD & LDT for autoimmune diseases market revenue estimated and forecast, by type, 2018 - 2030 (USD million)
  • Table 4 U.S. IVD & LDT for autoimmune diseases market revenue estimated and forecast, by application, 2018 - 2030 (USD million)
  • Table 5 U.S. IVD & LDT for autoimmune diseases market revenue estimated and forecast, by technology, 2018 - 2030 (USD million)
  • Table 6 Company market share, 2024

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 U.S. IVD & LDT For Autoimmune Diseases Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 U.S. IVD & LDT For Autoimmune Diseases Market: Type outlook and key takeaways
  • Fig. 15 U.S. IVD & LDT For Autoimmune Diseases Market: Type movement analysis & market share 2024 & 2030
  • Fig. 16 IVD market, 2018 - 2030 (USD Million)
  • Fig. 17 LDT market, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. IVD & LDT For Autoimmune Diseases Market: Technology outlook and key takeaways
  • Fig. 19 U.S. IVD & LDT For Autoimmune Diseases Market: Technology movement analysis & market share 2024 & 2030
  • Fig. 20 Immunoassays market, 2018 - 2030 (USD Million)
  • Fig. 21 Clinical Chemistry market, 2018 - 2030 (USD Million)
  • Fig. 22 Hematology market, 2018 - 2030 (USD Million)
  • Fig. 23 Coagulation market, 2018 - 2030 (USD Million)
  • Fig. 24 Microbiology market, 2018 - 2030 (USD Million)
  • Fig. 25 Molecular Diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 26 Others market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. IVD & LDT For Autoimmune Diseases Market: Application outlook and key takeaways
  • Fig. 28 U.S. IVD & LDT For Autoimmune Diseases Market: Application movement analysis & market share 2024 & 2030
  • Fig. 29 Addison's Disease market, 2018 - 2030 (USD Million)
  • Fig. 30 Ankylosing Spondylitis market, 2018 - 2030 (USD Million)
  • Fig. 31 Alopecia Areata market, 2018 - 2030 (USD Million)
  • Fig. 32 Rheumatoid Arthritis market, 2018 - 2030 (USD Million)
  • Fig. 33 Systemic Lupus Erythematosus market, 2018 - 2030 (USD Million)
  • Fig. 34 Systemic Sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 35 Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 36 Antiphospholipid Antibody Syndrome market, 2018 - 2030 (USD Million)
  • Fig. 37 Diabetes Type 1 market, 2018 - 2030 (USD Million)
  • Fig. 38 Crohn's Disease market, 2018 - 2030 (USD Million)
  • Fig. 39 Ulcerative Colitis market, 2018 - 2030 (USD Million)
  • Fig. 40 Narcolepsy market, 2018 - 2030 (USD Million)
  • Fig. 41 Multiple Sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 42 Uveitis market, 2018 - 2030 (USD Million)
  • Fig. 43 Others market, 2018 - 2030 (USD Million)
  • Fig. 44 Strategy Mapping market, 2018 - 2030 (USD Million)